T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
It is a novel oral NLRP3 inflammasome inhibitor
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
Sputnik M is a new member of the Sputnik vaccines family
The event was organized jointly by Oncology Forum and Fortis Cancer Institute, Delhi NCR
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Subscribe To Our Newsletter & Stay Updated
